Our News

Affinia Therapeutics to Present AFTX-201 for BAG3-Associated Dilated Cardiomyopathy (DCM) and Highlight Proprietary Capsid Engineering and Manufacturing Data at the American Society of Gene & Cell Therapy 2026 Annual Meeting

Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)

Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)

Affinia Therapeutics Receives European Medicines Agency Orphan Drug Designation for AFTX-201 in BAG3-Associated Dilated Cardiomyopathy (DCM)

Affinia Therapeutics Announces FDA Acceptance of IND Application to Advance AFTX-201 to a Phase 1/2 Trial for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)

Affinia Therapeutics to Participate in Upcoming Investor Conferences

Discover what it’s like to be an Affinian

Changing the world for patients – powered by science